Be Biopharma IPO

be.bio

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. The company's medicines address major hurdles of cell and gene therapies, and are durable, re-disable, and can be administered without toxic conditioning, thereby enabling healthcare sectors and patients to treat diseases like cancer, autoimmune conditions, and an enzyme deficiency. Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute.

Founded2020
Total Funding to Date$182.1MM
Register for Details

For more details on financing and valuation for Be Biopharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Be Biopharma Ticker Symbol

Be Biopharma does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Be Biopharma Stock Price

The stock price for Be Biopharma will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Major Investors for Be Biopharma

Atlas Venture
Ra Capital Management
Longwood Fund
Alta Partners
Takeda Ventures
Arch Venture Partners
Bristol Myers Squibb

Be Biopharma Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
4/14/2022 Series B $118MM raised $XXX.XX $XXX.XX
10/22/2020 Series A $64.1MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Other companies like Be Biopharma in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector